Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190158 · ClinicalTrials.gov registry record · Early Phase 1
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
A Early Phase 1 study of Type 2 Diabetes and Chronic Kidney Diseases, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06190158 is a Early Phase 1 study of Type 2 Diabetes and Chronic Kidney Diseases that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 125 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06190158, a Early Phase 1 study of Type 2 Diabetes and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral sodium suppression test
- DIAGNOSTIC_TEST Saline suppression test
- DIAGNOSTIC_TEST Captopril suppression test
- DIAGNOSTIC_TEST Dexamethasone suppression test
- DIAGNOSTIC_TEST Cosyntropin stimulation test
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2029-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06190158
The ClinicalTrials.gov registry entry for NCT06190158 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Oral sodium suppression test is the first listed.
NCT06190158 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06190158 about?
NCT06190158 is a clinical study titled "Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease". The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
What is the current status of trial NCT06190158?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 125 participants. The study started on 2024-05-15. Estimated completion is 2029-07-31.
What conditions does trial NCT06190158 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Chronic Kidney Diseases.
What interventions are being tested in trial NCT06190158?
The interventions under investigation include: Oral sodium suppression test (DIAGNOSTIC_TEST), Saline suppression test (DIAGNOSTIC_TEST), Captopril suppression test (DIAGNOSTIC_TEST), Dexamethasone suppression test (DIAGNOSTIC_TEST), Cosyntropin stimulation test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06190158?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06190158 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
SGLT2i, Hepatic Glucose Production, and SNS
RECRUITING · Early Phase 1
-
Precision Dosing of Metformin in Youth With T2D
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Antioxidant Treatment of Type 2 Diabetes
COMPLETED · Early Phase 1
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.